Disrupted Brain Connectivity in Newborns Following Antenatal Opioid Exposure.  De Asis-Cruz J, Kim JH, Kapse K, Wu Y, Merhar SL, Bann CM, Newman JE, Mack N, DeMauro SB, Ambalavanan N, Lorch SA, Wilson-Costello D, Poindexter BB, Peralta-Carcele…

Procedural Pain Assessments for Neonates at Risk of Neonatal Opioid Withdrawal Syndrome: A Scoping Review.  Lavergne, Julianna BScN, RN*; Langman, Erin MLIS†; Mansell, Deborah PhD, RN*; Dol, Justine PhD‡; Benoit, Britney PhD, RN*.  The C…

Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood.  Monfared A, Murrell DE, Shah DS, Hoang M, Brown SD, Harirforoosh S.  Toxicol Rep. 2025 Jul 20;15:102093. doi: 10.1016/j.toxrep.2025.102093. PM…

Optimizing pharmacologic treatment for neonatal opioid withdrawal syndrome (OPTimize NOW): a symptom-based dosing approach study protocol for a multi-center, cluster crossover design randomized controlled trial.  Young LW, Babineau DC, Das A…

The impact of the number of non-opioid psychotropic medications and their co-exposures during pregnancy on short-term outcomes in full-term neonates.  Isohata H, Miura S, Yamazaki Y, Goto H, Yoshimura Y, Hattori K, Shimaoka T, Sekiguchi K, Nak…

Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome.  Bibi S, Singh R, Breeze JL, Nelson J, Kraft WK, Davis JM.  Front Pediatr. 2025 Aug 11;13:1527276. doi: 10.3389/fped.2025.1527276. PMID…